title: Efficacy and safety of S-1 (tegafur, gimeracil, and oteracil potassium) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
abstract: OBJECTIVE
  This study evaluated the efficacy and safety of the combination drug tegafur, gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients.
  
  
  METHODS
  Patients with pathologically or cytologically newly diagnosed lung squamous cell carcinoma (n=106) were randomly assigned to receive the combination of tegafur, gimeracil, and oteracil potassium (40mg/m(2), BID, d1-28, repeated every 6 weeks for 4 cycles) and concurrent 3D-conformal radiotherapy (60Gy; experimental group), or gemcitabine (800-1000mg/m(2), d1 and d8) repeated every 21 days for 4 cycles as well as 3D-conformal radiotherapy (control group).
  
  
  RESULTS
  The overall response rate (complete and partial responses) of the experimental group was 68.6%, which was significantly higher than that of the control group (38.5%; P=0.002). The median progression-free survival rates of the experimental and control groups were 11.8 months (95% confidence interval [CI]: 8.0-22.4) and 7.8 months (95% CI, 6.9-9.2), respectively (P=0.017). Adverse reactions included grade I/II radiation esophagitis and pneumonitis, with good tolerance. Grade III/IV adverse reactions of the experimental and control groups were leucopenia (20% cf. 56.6%, respectively; P=0.027), thrombocytopenia (3.9% cf. 25%; P=0.037), and gastrointestinal reaction (1.9% cf. 3.5%; P=0.35).
  
  
  CONCLUSIONS
  The efficacy of concurrent combination chemotherapy with tegafur, gimeracil, and oteracil potassium (S-1) and 3D-conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients was excellent, and all toxicities were well tolerated. This treatment might be considered a main regimen in the management of squamous cell carcinoma of the lung in elderly patients.
authors.affiliation: Department of Medical Oncology, Zaozhuang Municipal Hospital, 277102 Zaozhuang, China. Electronic address: wang1968tao@163.com.
authors.forename: T
authors.initials: T
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Zaozhuang Municipal Hospital, 277102 Zaozhuang, China.
authors.forename: S-F
authors.initials: SF
authors.lastname: Zhang
authors.affiliation: Department of Medical Oncology, Zaozhuang Municipal Hospital, 277102 Zaozhuang, China.
authors.forename: M-Q
authors.initials: MQ
authors.lastname: Qiu
authors.affiliation: Shandong University, 250011 Jinan, China.
authors.forename: Q-L
authors.initials: QL
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D020266:Radiotherapy, Conformal / Q000009:adverse effects; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D011725:Pyridines; C586502:tegafur-gimeracil-oteracil; D005641:Tegafur; D010094:Oxonic Acid
keywords: 3D-CRT; Carcinome épidermoïde du poumon; Gemcitabine; Radiothérapie conformationnelle tridimensionnelle; S-1; Squamous cell lung carcinoma